From the essiactea.com Home Page
For full info see http://www.essiactea.com
For more info see http://www.kathykeeton-cancer.com
Part 4 of 5
     returned at a gallop." Within three weeks, her racking cough had 
vanished and she
     could walk unaided. "In the months before her death, she went on 
television with me
     to tell the nation about hydrazine sulfate. The National Cancer 
Institute stopped
     trashing hydrazine sulfate and began referring inquiries to the UCLA 
Medical School
     team whose work had validated the effectiveness of the drug long before 
Erna
     Kamen began taking it." Jeff attributes his mothers death months later 
to her being
     "mistakenly taken off hydrazine sulfate and subjected to an unproven 
experimental
     substance." With cancer patients, hydrazine sulfate is usually 
administered orally in
     60-milligram capsules or tablets, approximately one to two hours before 
meals. It is
     given at first once a day for several days, then twice a day, then three 
or four times
     daily, depending on the patient's response and the physician's judgment. 
On such a
     regimen, many terminal and semiterminal patients have derived 
considerable benefit,
     although patients in the early stages of the disease derive the most 
benefit from the
     treatment.
     Approximately half of the patients to whom the drug is properly 
administered in the
     early stages of the disease show an almost immediate weight gain and 
reversal of
     symptoms; in some instances, the tumor eventually disappears. The common 
types
     of cancer most frequently reported to benefit from hydrazine sulfate 
therapy are
     recto-colon cancer, ovarian cancer, prostatic cancer, lung 
(bronchogenic) cancer,
     Hodgkin's disease and other lymphomas, thyroid cancer, melanoma, and 
breast
     cancer. Some less common types of cancer also benefit.
     "Whether hydrazine sulfate should be used in conjunction with other 
agents seems to
     be dependent on whether these agents are doing the patient any 
demonstrable
     good," according to Dr. Gold. "In the instances in which these agents 
have been
     doing good, hydrazine sulfate should be used in conjunction with them.
     However and especially with those cases on toxic drugs in instances in 
which
     the drugs have been doing no evident good, it is probably best to 
withdraw such
     drugs and use hydrazine sulfate alone." Many alternative therapists 
disagree. They
     see hydrazine sulfate as mainly an adjunctive treatment, albeit a 
potentially powerful
     one.
     Critics have made much of the fact that hydrazine sulfate, a common 
industrial
     chemical, is found in such products as rocket fuel, insecticides, and 
rust-prevention
     agents. For medical purposes, however, the salt is refined, purified, 
and used in
     reagent-equivalent grades. Given to patients in minuscule amounts, it 
occasionally
     produces mild, transient side effects such as nausea, dizziness, itching 
of the skin,
     drowsiness, and euphoria, but such side effects are minimal, especially 
when
     compared with the devastating effects of standard chemotherapy.
     A very small percentage of patients undergoing long-term, high dosage 
hydrazine
     sulfate therapy experience pain or temporary numbness in their 
extremities, but this
     condition is quickly controlled by reducing the dosage and administering 
vitamin B6.
     In no known cases has hydrazine sulfate depressed or destroyed white 
blood cells
     or bone marrow, as conventional chemotherapy often does. In general, 
toxicity has
     been exceedingly low or nil.
     The most recent study of this drug, however, concluded that hydrazine 
sulfate
     appears not to be beneficial and may even have neurological side 
effects. This study
     involved a nationwide, twenty-month trial with 291 advanced 
non-small-cell lung
     cancer patients, all of whom received chemotherapy. In the double-blind 
phase, half
     were given hydrazine sulfate, while the other half received a placebo. 
Patients
     receiving hydrazine sulfate had a median survival of 7.62 months, while 
the
     comparable figure for those on placebo was 7.5 months. Hydrazine sulfate 
had no
    See part 5 of 5
    ---
--- Maximus 2.00
---------------